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Background: Several lines of evidence indicate that Sirt1, a class III histone deacetylase (HDAC) is implicated in the
initiation and progression of malignancies and thus gained attraction as druggable target. Since data on the role of
Sirt1 in pancreatic ductal adenocarcinoma (PDAC) are sparse, we investigated the expression profile and prognostic
significance of Sirt1 in vivo as well as cellular effects of Sirt1 inhibition in vitro.
Methods: Sirt1 expression was analyzed by immunohistochemistry in a large cohort of PDACs and correlated with
clinicopathological and survival data. Furthermore, we investigated the impact of overexpression and small
molecule inhibition on Sirt1 in pancreatic cancer cell culture models including combinatorial treatment with
chemotherapy and EGFR-inhibition. Cellular events were measured quantitatively in real time and corroborated by
conventional readouts including FACS analysis and MTT assays.
Results: We detected nuclear Sirt1 expression in 36 (27.9%) of 129 PDACs. SIRT1 expression was significantly higher
in poorly differentiated carcinomas. Strong SIRT1 expression was a significant predictor of poor survival both in
univariate (p = 0.002) and multivariate (HR 1.65, p = 0.045) analysis. Accordingly, overexpression of Sirt1 led to
increased cell viability, while small molecule inhibition led to a growth arrest in pancreatic cancer cells and
impaired cell survival. This effect was even more pronounced in combinatorial regimens with gefitinib, but not in
combination with gemcitabine.
Conclusions: Sirt1 is an independent prognosticator in PDACs and plays an important role in pancreatic cancer cell
growth, which can be levered out by small molecule inhibition. Our data warrant further studies on SIRT1 as a
novel chemotherapeutic target in PDAC.
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Pancreatic ductal adenocarcinoma (PDAC) is the fourth
leading cause of cancer related deaths in the United States.
While substantial progress has been made in the under-
standing of pancreatic cancer biology [1], therapeutic
concepts still provide only modest benefit [2]. The over-
all 5-year survival rate is approximately 5% [3]. Surgical
resection is the only efficient and potentially curative* Correspondence: albrecht.stenzinger@med.uni-heidelberg.de
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distribution, and reproduction in any mediumtreatment option with 5-year survival rates of around
20% in patients with resectable tumors, but can only be
applied in approximately 15-20% of the cases emphasizing
the urgent need for early detection strategies [4].
The main prognosticators for surgically resectable
PDACs are location, tumor size, resection margin, nodal
status, and histological grade. Although these risk factors
have been proven to be clinically useful, their ability to
reliably predict outcome is limited and mainly reflects
tumor distribution rather than tumor biology [4].
Hence, numerous studies have been conducted to iden-
tify novel biomarkers that aid outcome prediction and totral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ment [5].
Sirt1 (homolog of yeast silent information regulator,
Sir2), an isoform of enzymes of the silent information
regulatory family (sirtuins), is an evolutionary conserved
NAD dependent histone/protein deacetylase (class III
HDAC) that mediates epigenetic silencing by modification
of lysine residues of histones and deacetylation of numer-
ous non-histone substrates. One of the first substrates
identified was p53, whose deacetylation was reported to
repress p53-dependent apoptosis in response to cellular
stress and DNA damage [6,7]. Meanwhile, many other tar-
gets have been identified, including Ku70 [8], PTEN [9],
p73 [10], RelA/p65 [11], FOX01, FOX03a, and FOX04
[12], NICD [13], hypoxia-inducible factors HIF-1α, -2α
[14,15], β-catenin [16], XPA [17], SMAD7 [18], and
cortactin [19]. Deacetylation of these targets regulates cell
survival, proliferation, and angiogenesis. Overexpression
of sirtuins was initially reported to increase lifespan in
budding yeast, Caenorhabditis elegans, and Drosophila
melanogaster [20-22] but for the latter two the findings
were challenged by a recent study of Burnett and col-
leagues [23].
The functional role of Sirt1 in cancer is equivocal and
suggested to be context dependent [24]. Although there
are convincing studies that argue for a tumour suppressive
role of Sirt1, recent data provide functional evidence that
Sirt1 has oncogenic properties in neuroblastomas by facili-
tating n-myc stabilization [25]. Serrano [26] reported that
transgenic Sirt mice crossed with PTEN-null mice were
observed to develop thyroid and prostate cancer further
arguing for a tumor promoting function of Sirt1.
While several studies found deregulation of Sirt1 in vari-
ous tumor entitites including ovary, prostate, gastric,
colon, hepatocellular carcinoma as well as melanoma and
glioblastoma [27], comprehensive in vivo data in pancre-
atic cancer is still missing. Reports that explore Sirt1 func-
tion in pancreatic cancer are sparse [28].
Hence, we set out to comprehensively investigate Sirt1
expression in a large series of PDACs, its relationship to
survival and to assess the functional relevance in cell
culture models.
Methods
Patients and samples
Tissue samples from 129 patients who underwent partial
pancreaticoduodenectomy for primary pancreatic ductal
adenocarcinoma between 1991 and 2000 were retrieved
from the database of the Pathology Department of the
Charité University Hospital. The study was approved by
the Charité University Ethics Committee (No. EA1/06/
2004).
Median age of patients with pancreatic cancer was
65 years (range 35–80 years). Follow-up data regardingoverall survival were available for 113 patients. Within the
follow up time, 89 patients (78.8%) died after a mean follow
up time of 22.1 months. Mean follow-up time of patients
still alive at the endpoint of analysis was 54.0 months.
Cases were staged according to "TNM Classification of
Malignant Tumours. 7th edition" [29] and were graded as
recommended by the WHO [30].
Tissue microarray construction
Of all PDACs 3-μm sections were cut and stained with
H&E. Three representative areas from the tumor center
and invasive margins were marked by a board certified
pathologist (W.W.). For each case three tissue cores (1.5-
mm diameter) from the selected representative tumor
areas were punched out of the sample tissue blocks and
embedded into a new paraffin array block using a tissue
microarrayer (Beecher Instruments, Woodland, CA).
Immunohistochemistry
For immunohistochemical detection of Sirt1 on tissue sam-
ples, a monoclonal rabbit antibody (dil.: 1:100, clone E104,
Cat# 1104–1; Epitomics, Burlingame, CA, USA) was used.
After heat-induced antigen retrieval, slides were incubated
with the primary antibody at 4 degree Celsius overnight.
Bound antibody was detected by a streptavidin–biotin sys-
tem (BioGenex, San Ramon, CA, USA). For colour develop-
ment, a Fast Red system (Sigma, Deisenhofen, Germany)
was used. Omission of the primary antibody served as
negative control. The slides were cover slipped after
counterstaining.
Nuclear staining of Sirt1 was scored by applying a semi-
quantitative immunoreactivity scoring (IRS) system, as de-
scribed previously. Briefly, the intensity of staining and
percentage of cells stained were evaluated separately. The
IRS for each individual case ranging from 0 to 12 was cal-
culated by multiplication of the intensity and frequency
scores. Cases exhibiting an IRS from 0–6 were combined
in one group (‘Sirt1 low’), cases with an IRS of > 6 were
combined in a ‘Sirt1 high’ group. Staining of tissue slides
was evaluated by experienced pathologists (WW and AS)
blinded towards patient characteristics and outcome.
Cell culture
The human pancreatic cancer cell lines PANC-1 (#CRL-
1469) and MiaPaCa-2 (#CRL-1420) were obtained from the
American Type Culture Collection (ATCC, Rockville, MD,
USA) and cultured in Dulbecco's modified Eagle's medium
supplemented with 10% fetal bovine serum and P/S. For
the MIA-PaCa-2 cells, additionally 2.5% horse serum and
5 ml NaHCO3 (0.75 mg/ml final concentration) were used.
These two cell lines were chosen, since PANC-1 is a proto-
typical Gemcitabine resistant cell line, while Mia-PaCa-2 is
known to retain some Gemcitabine sensitivity.
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Cambinol (Cat#566323) was purchased from Merck
(Darmstadt, Germany), Gefitinib (Cat#PKI-GFTB2-200)
was obtained from Biaffin (Kassel, Germany) and Nico-
tinamide from Sigma (Taufkirchen Germany).
Plasmids, siRNA and transfections
The SIRT1/2 and GFP control expression constructs were
obtained from Addgene. For SIRT1, expression of the
FLAG-tagged SIRT1 open reading frame was under the
control of an SV40 promotor, allowing physiological levels
of SIRT1 expression in cells not harbouring the Large-T
antigen (pECE-FLAG-SIRT1, constructed by Michael
Greenberg [31]). GFP (Addgene plasmid 13031, cons-
tructed by Doug Golenbock) was cloned in a pcDNA3 vec-
tor, allowing high protein expression controlled by CMV
promotor. Predesigned siRNAs for Sirt1 were purchased
from Dhamarcon (ON-TARGETplus SMARTpool, human
Sirt1, Cat# L-003540-00-0010). The target sequence is as
follows: GCGAUUGGGUACCGAGAUA. A non-target
scambled siRNA was used as negative control (all stars
negative control siRNA; Cat#1027281, Qiagen, Hilden
Germany). After 72 h, the efficacy of transfection was
checked by immunoblotting.
All transfections were performed using oligofectamine
(dilution: 1:200; Invitrogen, Karlsruhe, Germany) according
to the manufacturers’ protocol.
MTT assay
Cell viability was measured 72 hrs after pSirt1 transfec-
tion by the MTT (3-[4,5-dimethylthylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide; Sigma, Munich, Germany)
assay according to the manufacturer’s instructions.
Briefly, 20 μl of 5% MTT solution in PBS was added to
each well. After 4-6 h of incubation at 37 °C, the active de-
hydrogenase in viable mitochondria reduced the tetrazo-
lium ring of MTT to form a blue-colored precipitate, which
was then dissolved in 150 μl 50% dimethyl sulfoxide / 50%
Ethanol and quantified spectro-photometrically at 570 nm.
Real time analysis
The PANC-1 and MiaPaCA-2 cell lines were seeded in des-
ignated 96 well E-plates (Roche, Penzberg, Germany).
Impedance-based real time detection of cellular proliferation
was conducted using the xCELLigence system Real-Time
Cell Analyzer RTCA-SP (Roche Diagnostics, Penzberg,
Germany). The impedance readout as recorded by the
xCELLigence system is converted into arbitrary cell index
(CI)-values corresponding to each well. The CI value is de-
fined as relative change in measured electrical impedance to
represent cell status, and is directly proportional to quantity,
size, and attachment forces of the cell. Recording of CI and
subsequent normalization of the cell index (normalized cellindex, NCI) was performed using the RTCA Software 1.2
(Roche).
The NCI is calculated using the equation: NCI =CI at a
given time point divided by the CI at the normalization
time point. Hence, the NCI equals 1 at the normalization
time point. Background impedance caused by the media
was determined in each well before seeding the cells and
subtracted automatically by the RTCA software following
the equation: CI = (Ri – R0)/15 with Ri as the impedance at
any given time point and R0 as the background resistance.
FACS analysis
The effect of Cambinol and Gefitinib on the cell-cycle
profile of pancreatic cancer cells was assessed by flow cy-
tometry. PANC-1 and MiaPaCa-2 were exposed to various
concentrations of Cambinol or Gefitinib or combinations
thereof for 14 hrs and 72 hrs and the cell cycle profiles
were determined by flow cytometry as described previ-
ously [32]. Briefly, the cells were harvested with versene,
treated with a citric acid buffer (2.1% citric acid and 0.5%
Tween 20 in dH2O), and stained using a phosphate buffer
(pH 8.0, 7.2 g Na2HPO4_ 2H2O in 100 mL dH2O)
containing DAPI. DNA-histograms were obtained by flow
cytometry (PAS II, Partec; Muenster, Germany) and the
Multicycle program (Phoenix Flow Systems, San Diego,
USA) was used for histogram analysis. Each measurement
was done in triplicate.
Immunoblotting
Treated PANC-1 and MiaPaCa-2 cells were lysed in cell
lysis buffer (#9803, New England.
Biolabs, Frankfurt, Germany) containing 20 mM Tris–
HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM
EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM
beta-glycerophosphate, 1 mM Na3VO4, 1 μg/ml leupeptin
as well as Protease inhibitor Mix G (#39101.01; Serva Elec-
trophoresis, Heidelberg, Germany). Prepared protein lysates
(30 μg) were denaturated at 95 °C, separated in sodium
dodecyl sulfate polyacrylamide (SDS)-polyacrylamide gels
(10%) by electrophoresis and electro-transferred to a
polyvinylidene difluoride (PVDF) membrane. After transfer,
samples were blocked with 5% MP-PBST for 1 h and
probed with antibodies against Sirt1 (dil.: 1:5000, clone
E104, Cat# 1104–1; Epitomics), cleaved PARP (dil.: 1:300,
Cat# 9541, clone Asp214 ; Cell Signaling), pospho-H2AX
pSer139 (dil: 1:000, Cat# 05–636, clone JBW 301; Millipore)
and beta-Actin (dil: 1:10000, Cat#A5441, clone AC-15;
Sigma) diluted in 5 MP-PBST (5% milk powder, Phosphate-
buffered saline/Tween) and incubated at 4 °C overnight.
The appropriate secondary antibody was applied
[1:20000; horseradish peroxidase anti-mouse and horse-
radish peroxidase anti-rabbit] at room temperature for
1 hr. Visualization was performed by enhanced chemilu-
minescence (Amersham Bioscience, Freiburg, Germany).
Table 1 Clinico-pathological characteristics of the PDAC
study cohort: correlation with Sirt1 expression
Characteristics All cases SIRT1 low SIRT1 high p-value
All cases
129 93 (72.1%) 36 (27.9%)
Age 0.401
≤65 years 65 (50.4%) 48 (73.8%) 17 (26.2%)
>65 years 64 (49.6%) 48 (70.3%) 17 (29.7%)
WHO stage 0.871
I 12 (9.3%) 9 (75%) 3 (25%)
IIA 17 (13.2%) 13 (76.5%) 4 (23.5%)
IIB 91 (70.5%) 66 (72.5%) 25 (27.5%)
III 5 (3.9%) 3 (60.0%) 2 (40.0%)
IV 4 (3.1%) 2 (50.0%) 2 (50.0%)
Tumour stage 0.793
T1 / / /
T2 24 (18.6%) 18 (75.0%) 6 (25.0%)
T3 100 (77.5%) 72 (72.0%) 28 (28.0%)
T4 5 (3.9%) 3 (60.0%) 2 (40.0%)
Nodal status 0.520
N0 31 (24.0%) 22 (71.0%) 9 (29.0%)
N1 98 (76.0%) 71 (72.4%) 27 (27.6%)
State of metastasis 0.310
M0 125 (96.9%) 91 (72.8%) 34 (27.2%)
M1 4 (3.1%) 2 (50.0%) 2 (50.0%)
Grade 0.001
G1 8 (6.2%) 6 (75.0%) 2 (25.0%)
G2 64 (49.6%) 55 (85.9%) 9 (14.1%)
G3 57 (44.2%) 32 (56.1%) 25 (43.9%)
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1.32 software (National Institutes of Health, Bethesda,
MD) after scanning of the films.
Statistical analysis
For correlation analysis of Sirt1 expression with clinic-
pathological parameters, the Fisher’s exact test or χ2 test
for trends was applied. For univariate analysis we used the
Kaplan-Meier method and a Log-rank test to probe for
significance. For multivariate survival analysis the Cox
proportional hazard method was used. Variables found in
univariate analysis to be significantly related to survival
were included in the Cox models. For statistical analysis of
cell cycle and MTT data, a two-tailed t-test was applied.
For all statistical tests and methods, p-values of <0.05 were
considered statistically significant. Statistical analyses were
carried out with SPSS 15.0 and Graph Pad Prism 4.
Results
Patients’ and tumor characeristics
The patients’ demographics are listed in Table 1. The mean
follow-up time was 22.1 months. During the study period,
89 patients died. The median survival was 13.4 months
and the median time to death was 10.3 months (range: 1.2
to 41.93 months). 65 patients were below the age of 65 and
64 patients above the age of 65 (median 65 yrs). 118 PDAC
were located in the head of the pancreas and 11 in the pan-
creatic corpus or tail.
Sirt1 expression in PDACs
The specificity of the antibody used for immunohisto-
chemistry was corroborated by siRNA-mediated knock-
down of Sirt1 in MiaPaCa-2 and PANC-1 cells and
subsequent immunoblotting with the Sirt1 antibody.
The knock-down led to complete abrogation of the
immunosignal as shown in Figure 1.
As exemplified in Figure 2, we observed a nuclear
localization of Sirt1 in PDAC with a low expression
(Figures 2A and B) in 72.1% and a high expression
(Figures 2C and D) in 27.9% of the cases, respectively.
Sirt1 was expressed by tumor cells with varying degrees
of nuclear atypia, forming either neoplastic duct like
structures, solid masses or single cell infiltrates within
desmoplastic stroma.
When analyzed with regard to the morphological fea-
tures and tumor extent, the expression of Sirt1 was sig-
nificantly correlated to poor histological differentiation
(p = 0.001). There was no statistical difference in Sirt1
expression between early stage and advanced stage tu-
mors (WHO stage and TNM stage, Table 1).
Univariate survival analysis
By univariate survival analysis (Table 2), patients’ outcome
was correlated with both tumor TNM and WHO stage(p = 0.001 and 0.003, respectively). A borderline significance
was observed for histological grade (p = 0.058).
The Kaplan-Meier analysis (Figure 2E) of grouped
Sirt1 expression (IRS ≤6, >6) was highly prognostic of
poor overall survival for those patients with high Sirt1
expression with a mean postsurgical survival of 13.0 vs.
54.1 months (log-rank test: p = 0.002).
Multivariate survival analysis
In multivariate Cox regression analysis (Table 3), high
Sirt1 expression was significantly related to shorter over-
all survival (HR 1.647, 95%CI 1.010-2.687, p = 0.045), in-
dependently of the degree of histological differentiation
and WHO stage.
Cellular effects of Sirt1 overexpression
To test whether high Sirt1 expression also has a cellular ef-
fect in vitro, we performed overexpression experiments in
both cell lines, MiaPaCa-2 and PANC-1, respectively, using
Figure 1 Immunblots with the antibody against Sirt1. While
endogenous Sirt1 levels were detected by the antibody, knockdown
of Sirt1 by siRNA in MiaPaCa-2 and PANC-1 cells led to a complete
abrogation of the immunosignal indicating that the antibody binds
specifically to its target protein.
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Figure 3A) shows immunoblots for endogenous and
overexpressed Sirt1 in both cell lines. Cells overexpressing
Sirt1 showed a markedly stronger immunosignal compared
to their untransfected counterparts, which can also be
depicted quantitatively as displayed in Figure 3B). Compared
to GFP transfected cells, both cell lines showed statistically
significantly increased amounts of viable, proliferatingFigure 2 Sirt1 expression in PDAC. A) (overview, x5) and B (x20) show n
and D (x20) display a strong nuclear Sirt1 immunosignal. E) Kaplan-Meier c
p-value was calculated in a log-rank test. The red line indicates tumors of p
those with low Sirt1 expression.cells upon transfection with flag-tagged Sirt1 as determined
by MTT assay (Figure 4) and Xcelligence proliferation
assays (data not shown).
Nicotinamide and gefitinib treatment in cells with
endogenous or overexpressed Sirt1
Inhibition of Sirt1 by increasing concentrations of nico-
tinamide led to a stepwise decrease of viable cells as
depicted in Figure 5. Gefitinib treatment with concentra-
tions of 50 μM showed similar effects as observed for
the application of 25 mM nicotinamide. Interestingly,
combinatory treatment with 50 μM gefitinib and 25 mM
or 40 mM nicotinamide showed a synergistic effect on
cell viability, which was observed in both cell lines.
Next, we asked whether inhibition of Sirt 1 by nicotina-
mide may counterbalance the beneficial effect on cell sur-
vival triggered by Sirt1 overexpression. We found that
application of 10 mM and lower concentrations of nicotina-
mide, which in untransfected cells already showed a strong
decrease of viable cell fractions compared to controls did
not influence cell viability in cells overexpressing Sirt1, while
higher concentrations of nicotinamide (Figure 6) abrogated
increased cell viability mediated by overexpressed Sirt1.
Cellular effects of cambinol, gemcitabine and gefitinib
treatment
Proliferation assay
Real time proliferation assays revealed an inhibition of cell
growth of Mia-PaCa-2 cells and PANC-1 cells over a time
period of 72 hrs upon treatment with cambinol. While for
Mia-PaCa-2 comparably lower concentrations of cambinol
(25 and 50 μM) were necessary to achieve this effect, for
PANC-1 cells concentrations up to 100 μM had to beuclear Sirt localization with a weak staining signal. C) (overview, x5)
urve for postsurgical survival according to Sirt1 expression. The given
atients with high Sirt1 expression whereas the blue line indicates
Table 2 Univariate survival analysis for Sirt1 expression and clinico-pathological parameters in PDAC
Cases Events Mean survival (months) Standard error Log-rank-test (p-value)
Age at diagnosis <=65 years 56 42 50.1 10.5 0.564
>65 years 57 47 25.1 4.4
WHO stage I 11 8 29.4 9.8 0.001
IIA 17 10 52.8 11.9
IIB 78 64 33.7 7.0
III 3 3 5.6 0.8
IV 4 4 11.9 4.1
Tumor stage T1 / / / /
T2 22 17 29.6 6.8 0.003
T3 88 69 39.6 7.3
T4 3 3 5.6 0.8
Nodal status N0 30 20 43.3 8.8 0.060
N1 83 69 32.2 6.6
State of metastasis M0 109 85 42.4 6.8 0.268
M1 4 4 11.9 4.1
Grade G1 7 6 16.8 2.5 0.058
G2 54 39 37.3 6.0
G3 52 44 29.7 7.9
SIRT1-expression low 81 58 54.1 8.9 0.002
high 32 31 13.0 1.7
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led to a synergistic inhibitory effect on cell growth for
both cell lines. As in the previous experiment slightly
higher concentrations for cambinol as well as for gefitinib
were used to achieve comparable results in PANC-1 cells.
As expected in Mia-PaCa-2 comparably low concentra-
tions of gemcitabine alone led to strong growth inhibitoryTable 3 Multivariate survival analysis (Cox regression
model) including tumor stage and grade in PDAC
Overall survival
HR 95%CI p-value
WHO stage
I 1
IIA 0.57 0.22-1.45
IIB 1.11 0.53-2.24
III 4.92 1.20-20.16
IV 1.88 0.56-6.33 0.029
Grade
G1/G2 1
G3 1.28 0.81-2.03 0.298
SIRT1-expression
low 1
high 1.65 1.01-2.69 0.045effects, while in PANC-1 comparably higher concentra-
tions were necessary (data not shown). Although we
tested a multitude of different treatment schemes, a syner-
gistic effect for treatment with gemcitabine and cambinol
in combination was not observed (data not shown).
Cell cycle analysis
To determine the nature of the cellular growth inhib-
ition, we performed FACS analyses. For PANC-1 cells
treated with either cambinol or gefitinib alone or in
combination, a sub-G1 peak was observed indicating apop-
tosis (Figure 8A), which was also evident by demonstrating
cleaved PARP by immunoblot (Figure 8B). Cell cycle ana-
lysis of Mia-Paca-2 cells showed a cell cycle arrest for differ-
ent concentrations of cambinol (25 and 50 μM) and for a
combinatory regimen of cambinol and gefitinib (Additional
file 1: Figure S1), but in our experimental setting no appar-
ent apoptosis induction.
Senescence analysis
Upon treatment with cambinol, we observed for both
cell lines a population of growth-arrested cells with a
flattened, elongated appearance and extended cellular
protrusions (Additional file 2: Figure S2A). As exempli-
fied in Additional file 2: Figure S2B, immunblotting re-
vealed a marked upregulation of y-H2AX in Mia-Paca-2
cells indicating a senescent phenotype.
Figure 3 Immunblots with the antibody against Sirt1 for MiaPaCa-2 and PANC-1. A) Endogenous protein levels showed a comparably
weaker immunosignal than cells overexpressing Sirt1. B) The blots were scanned and analysed quantitatively using ImageJ. The values were
normalized for pGFP. The graphs show strongly increased immunosignal densities for cells that overexpress Sirt1.
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Immunoblotting of cells treated with cambinol 100 or
200 μM revealed an extinction of the Sirt1 protein as
compared to controls treated with DMSO only (Figure 9).
While this effect was repeatedly observed in Mia-Paca-2
cells after 24 hrs, 48 hrs and 72 hrs of cambinol treatment,
for PANC-1 cells only high concentrations of cambinol
applied for 72 hrs led to a similar effect.
Discussion
This is the first study that demonstrates Sirt1 to be an
independent prognosticator in PDAC with high Sirt1
expression indicating poor outcome. Moreover, our data
argue for a functional role of Sirt 1 during tumorigen-
esis indicating that Sirt1 is not only a biomarker but a
potentially oncogenic protein in the PDAC context,
whose overexpression leads to increased cell viability in
both cell lines, while pharmacological inhibition leads to a*
A
Figure 4 Cell viability of MiaPaCa-2 and PANC-1 cells assessed by MT
respectively. A) MiaPaCa-2, B) Panc-1. The test was carried out 3 days afte
three independent experiments. *P < 0.05.concentration-dependent stepwise decrease of viable cells.
Cambinol treatment negatively interferes with cell cycle
progression (in MiaPaCa-2 cells) and induces apoptosis
(in PANC-1 cells) as well as senescence (both cell lines).
These observations are in line with Wauters et al. [33]
showing an enhancing effect for cell viability and regula-
tory function of Sirt1 for acinar-to-ductal metaplasia in
pancreatic carcinogenesis. The latter results also match
data presented by Zhao et al. [28] who reported that utiliz-
ing small hairpin RNA Sirt1 knockdown led to increased
apoptosis and senescence in PANC-1 cells. However, we
failed to observe a synergistic effect of Sirt1 inhibition with
Gemcitabine treatment as reported by Zhao et al. [28].
This divergent result may be attributed to the distinct
targeting approach in our study, which uses cambinol,
a clinically applicable drug with promising anti-cancer
effects in animal models of skin cancer and Burkitt’s
lymphoma as well as in several cancer cell lines [34].B
*
T test after treatment with flag-tagged Sirt1 and GFP,
r transfection. Bars represent average ± standard deviation (SD) of
**
*
*
*
*
*
*
*
*
*
A B
Figure 5 Cell viability of MiaPaCa-2 and PANC-1 cells assessed by MTT test after treatment with nicotinamide (NA) and gefitinib (Gef),
respectively. A) MiaPaCa2 cells, B) PANC-1 cells. Concentrations were used as indicated. Bars represent average ± standard deviation (SD) of
three independent experiments. *P < 0.05.
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centration-dependent loss of Sirt1 protein upon cambinol
treatment. The underlying cause for this effect, which
abrogates Sirt1-function, remains to be elucidated and
may be due to protein degradation.
Consistent with the results by Zhao et al. [28] obtained
by immunhistochemistry, qPCR and western blotting, we
observed a variable expression of Sirt1 in PDACs but did
not see a positive correlation of Sirt1 expression with age,
tumor size, and lymphatic spread. The different findings
may be explained by distinct cohort characteristics includ-
ing cohort size, age, and sex. However and in contrast to
Zhao et al., we observed a strong correlation with higherA
*
*
*
Figure 6 Cell viability of MiaPaCa-2 and PANC-1 cells assessed by MT
(NA) respectively. A) PANC-1 cells, B) MiaPaCa-2 cells. Concentrations wer
of three independent experiments. *P < 0.05.tumor grades, i.e. the less differentiated the cancer cells
are the more Sirt1 expression they exhibit. This finding is
of interest since there are reports that implicate Sirt1 in
the regulation of cellular differentiation and dedifferenti-
ation processes [35,36]. Dedifferentiation and the associ-
ated phenomenon of epithelial-to-mesenchymal-transition
play an essential role in the development of early local and
distant tumor spread. Observations that link high Sirt1 ex-
pression to poorly differentiated cancers were also made
by other investigators for hepatocellular carcinoma [37],
prostate cancer [38] and glioblastoma [39].
The association between high Sirt1 expression and poor
histological grade may also explain why in our cohort Sirt1B
*
*
*
T test after treatment with flag-tagged Sirt1 and/or nicotinamide
e used as indicated. Bars represent average ± standard deviation (SD)
Figure 7 Real-time cell proliferation assays (X-Celligence system). Dynamic cell proliferation of MiaPaCa-2 and PANC-1 cells plated on the E-
Plates 96 was monitored at 30-min intervals from the time of plating until the end of the experiment.
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http://www.biomedcentral.com/1471-2407/13/450expression is associated with poor outcome regardless
of the tumor stage as shown by its prognostic indepen-
dency in multivariate survival analysis. A Sirt1 positive
and poorly differentiated tumor may have acquired a
biological profile that allows for e.g. early systemic
spread of –clinically undetectable- micrometastases in
lymph nodes and distant organs leading to impaired
survival regardless of the tumor size and metastases
detected at the point of initial tumor diagnosis. A re-
cent study by Nalls and colleagues [40] showed that
SAHA-induced micro-RNA 34a (miR34a) expression
in human pancreatic cancer cells putatively directly
inhibited Sirt1 expression by binding within the 3’UTR
of Sirt1. On cellular level, restoration of miR34a ex-
pression led to growth inhibition as well as decreased
epithelial to mesenchymal transition (EMT) and inva-
sion. Although miR34a does not exclusively target
Sirt1, this recent study further argues for an oncogenicFigure 8 Cell cycle analysis and apoptosis in PANC-1 cells. A) Particula
sub-G1 peak indicating apoptotic cells. B) Immunoblotting for cleaved PARrole of Sirt1 in PDAC development. Recent results
obtained by Pramanik et al. corroborate this view [41].
Functional studies indicate that the subcellular
localization of Sirt1 might have functional implica-
tions in carcinogenesis. Wauters et al. [33] recently
provided evidence that there is nuclear to cytoplasmic
shuttling of Sirt1 in rat and mouse acinar cells with
potential tumorigenic implications in the acinar to
ductal metaplasia carcinogenesis model of PDAC.
They also reported on cytoplasmic localization of Sirt1
in exocrine cells of the human pancreas. However, in-
vestigating human tissue samples of fully developed
pancreatic ductal adenocarcinoma, we only detected
nuclear localized Sirt1. This may have several reasons.
One potential explanation might be that endogenous
cytoplasmic Sirt1 levels in comparison to nuclear ex-
pression levels are too low to be detected by our anti-
body. Another explanation would be that cytoplasmicrly combinatory therapy with gefitinib and cambinol led to a marked
P in PANC-1 cells. Reagents and concentrations as indicated.
Figure 9 Immunoblots of PANC-1 and MiaPaCa-2 cells show degradation of the target Sirt1 upon cambinol treatment.
Stenzinger et al. BMC Cancer 2013, 13:450 Page 10 of 12
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genic precursors and nuclear Sirt1 has its place in the
fully developed cancer. However, this has to be inves-
tigated in future functional studies.
Interestingly, following up the seminal work by Luo et al.
and Vasiri et al. [6,7], a very recent study by Li and co-
workers [42] explored the Sirt1-p53 axis in chronic mye-
loid leukemia (CML) and found that targeting of Sirt1 by
either shRNA or the small molecule inhibitor tenovin-6
resulted in increased levels of acetylated p53 in CML
CD34+ cells accompanied by increased transcriptional ac-
tivity of p53. Abrogation of Sirt1 led to growth inhibition
and reduced engraftment of the tumor cells. These effects
were even more pronounced when cells were synergistic-
ally treated with the tyrosine kinase inhibitor imatinib.
These data strengthen the view of a context-dependent
tumorigenic impact of Sirt1 as also suggested by our re-
sults. Since p53 aberrations are commonly involved in
PDAC tumorigenesis [43,44], it is tempting to speculate
whether Sirt1 inhibition may help to restore the remaining
functionally intact p53 pool. Indeed, recent data [45] indi-
cate that downregulation of Sirt1 by restoration of HIC1
(hypermethylated in cancer 1) leads to increased levels of
acetylated p53 and upregulated p21 in pancreatic cancer.
On cellular level, overexpressed HIC1, which in turn led to
downregulation Sirt1 resulted in cell cycle arrest and apop-
tosis. Loss of p53 function has also been implicated in re-
sistance to EGFR-targeting strategies [46], the latter having
a limited but significant role in the treatment of PDACs
[47]. Interestingly, we observed a synergistic impact of
combined Sirt1- and EGFR-inhibition suggesting a func-
tional interdependence in PDACs, whose molecular details
remain to be explored. In prostatic cancer cells Byles and
colleagues [48] observed Sirt1 to modulate EMT upon
EGF signalling via the induction of the transcription factorZEB1. Although it remains to be investigated whether this
mechanism works in PDACs, our data and these results
may additionally point to a therapeutic rationale for com-
bined EGFR/Sirt1 inhibition.
While a number of small molecule inhibitors of class I
and II HDACs are currently in clinical trials for the
treatment of malignancies of various organ origins [49],
SIRT1 inhibition is currently only investigated in a phase
I trial of patients with Huntington’s disease.
Conclusions
In conclusion, there is accumulating evidence that Sirt1
has an oncogenic role in PDACs and provided that further
studies are able to reproduce and extent the data presented
herein towards mouse model systems, a clinical trial for pa-
tients with PDAC, whose outcome and treatment options
are extremely limited for the vast majority of patients, may
be worthwhile to consider.
Additional files
Additional file 1: Figure S1. Cell cycle analysis of MiaPaCa-2 cells
showing growth arrest of tumor cells upon treatment as indicated.
Additional file 2: Figure S2. A) PANC-1 and MiaPaCa-2 cells show a
flattened phenotype with cellular protrusions. B) Immunoblots of
MiaPaCa-2 cells treated with cambinol and gefitinib as indicated showed
upregulation of y-H2AX.
Competing interest
The authors indicate no potential conflicts of interest.
Authors’ contributions
AS and WW designed the study, supervised research, analyzed the data, and
wrote the paper. AS, VE, and KL performed experiments and analyzed data. V
Ehemann performed cell cycle experiments. FK, BS, AW, BG, CK, MB and PN
provided patient samples, characterized some of the samples, collected data
and assisted in writing the paper. All authors read and approved the final
manuscript.
Stenzinger et al. BMC Cancer 2013, 13:450 Page 11 of 12
http://www.biomedcentral.com/1471-2407/13/450Author details
1Institute of Pathology, and National Center for Tumor Diseases (NCT),
University Hospital Heidelberg, Heidelberg, Germany. 2Institute of Pathology,
Charité-Universitätsmedizin, Berlin, Germany. 3Department of General, Visceral
and Transplantation Surgery, Charité-Universitätsmedizin, Berlin, Germany.
Received: 25 April 2013 Accepted: 25 September 2013
Published: 2 October 2013References
1. Hong SM, Park JY, Hruban RH, Goggins M: Molecular signatures of
pancreatic cancer. Arch Pathol Lab Med 2011, 135:716–27.
2. Hidalgo M: Pancreatic cancer. N Engl J Med 2010, 362:1605–1617.
3. Li D, Xie K, Wolff R, Abbruzzese JL: Pancreatic cancer. Lancet 2004,
363:1049–1057.
4. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M: Pancreatic cancer.
Lancet 2011, 378:607–20.
5. Singh P, Srinivasan R, Wig JD: Major molecular markers in pancreatic
ductal adenocarcinoma and their roles in screening, diagnosis,
prognosis, and treatment. Pancreas 2011, 40:644–652.
6. Vaziri H, Dessain K, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L,
Weinberg RA: hSIR2(SIRT1) Functions as an NAD-Dependent p53
Deacetylase. Cell 2001, 107:149–159.
7. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W:
Negative Control of p53 by Sir2alpha Promotes Cell Survival under
Stress. Cell 2001, 107:137–148.
8. Jeong J, Juhn K, Lee H, Kim SH, Min BH, Lee KM, Cho M, Park GH, Lee KH:
SIRT1 Promotes DNA Repair Activity and Deacetylation of Ku70. Exp Mol
Med 2007, 39:8–13.
9. Ikenoue T, Inoki K, Zhao B, Guan KL: PTEN Acetylation Modulates Its
Interaction with PDZ Domain. Cancer Res 2008, 68:6908–6912.
10. Dai JM, Wang ZY, Sun DC, Lin RX, Wang SQ: SIRT1 Interacts with p73 and
Suppresses p73-Dependent Transcriptional Activity. J Cell Physiol 2007,
210:161–166.
11. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW:
Modulation of NF-kappaB-Dependent Transcription and Cell Survival by
the SIRT1 Deacetylase. EMBO J 2004, 23:2369–2380.
12. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, Bultsma Y,
McBurney M, Guarente L: Mammalian SIRT1 Represses Forkhead
Transcription Factors. Cell 2004, 116:551–563.
13. Guarani V, Deflorian G, Franco CA, Kruger M, Phng LK, Bentley K, Toussaint L,
Dequiedt F, Mostoslavsky R, Schmidt MH: Acetylation-Dependent
Regulation of Endothelial Notch Signalling by the SIRT1 Deacetylase.
Nature 2011, 473:234–238.
14. Lim JH, Lee YM, Chun YS, Chen J, Kim JE, Park JW: Sirtuin 1 Modulates
Cellular Responses to Hypoxia by Deacetylating Hypoxia-Inducible
Factor 1alpha. Mol Cell 2010, 38:864–878.
15. Dioum EM, Chen R, Alexander MS, Zhang Q, Hogg RT, Gerard RD, Garcia JA:
Regulation of Hypoxia-Inducible Factor 2alpha Signaling by the Stress-
Responsive Deacetylase Sirtuin 1. Science 2009, 324:1289–1293.
16. Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J,
Bhimavarapu A, Luikenhuis S, de Cabo R, Fuchs C, Hahn WC, Guarente LP,
Sinclair DA: The SIRT1 Deacetylase Suppresses Intestinal Tumorigenesis
and Colon Cancer Growth. PLoS One 2008, 3:e2020.
17. Fan W, Luo J: Regulates UV-Induced DNA Repair through Deacetylating
XPA. Mol Cell 2010, 39:247–258.
18. Kume S, Haneda M, Kanasaki K, Sugimoto T, Araki S, Isshiki K, Isono M, Uzu
T, Guarente L, Kashiwagi A, Koya D: SIRT1 Inhibits Transforming Growth
Factor Beta-Induced Apoptosis in Glomerular Mesangial Cells via Smad7
Deacetylation. J Biol Chem 2007, 282:151–158.
19. Zhang Y, Zhang M, Dong H, Yong S, Li X, Olashaw N, Kruk PA, Cheng JQ,
Bai W, Chen J: Deacetylation of Cortactin by SIRT1 Promotes Cell
Migration. Oncogene 2009, 28:445–460.
20. Tissenbaum HA, Guarente L: Increased dosage of a sir-2 gene extends
lifespan in Caenorhabditis elegans. Nature 2001, 410:227–230.
21. Viswanathan M, Guarente L: Regulation of Caenorhabditis elegans lifespan
by sir-2.1 transgenes. Nature 2011, 477:E1–2.
22. Rogina B, Helfand SL: Sir2 mediates longevity in the fly through a
pathway related to calorie restriction. Proc Natl Acad Sci U S A 2004,
101:15998–6003.23. Burnett C, Valentini S, Cabreiro F, Goss M, Somogyvári M, Piper MD,
Hoddinott M, Sutphin GL, Leko V, McElwee JJ, Vazquez-Manrique RP, Orfila
AM, Ackerman D, Au C, Vinti G, Riesen M, Howard K, Neri C, Bedalov A,
Kaeberlein M, Soti C, Partridge L, Gems D: Absence of effects of Sir2
overexpression on lifespan in C. elegans and Drosophila. Nature 2011,
477:482–485.
24. Brooks CL, Gu W: How does SIRT1 affect metabolism, senescence and
cancer? Nat Rev Cancer 2009, 9:123–128.
25. Marshall GM, Liu PY, Gherardi S, Scarlett CJ, Bedalov A, Xu N, Iraci N, Valli E,
Ling D, Thomas W, van Bekkum M, Sekyere E, Jankowski K, Trahair T,
Mackenzie KL, Haber M, Norris MD, Biankin AV, Perini G, Liu T: SIRT1
Promotes N-Myc Oncogenesis through a Positive Feedback Loop
Involving the Effects of MKP3 and ERK on N-Myc Protein Stability. PLoS
Genet 2011, 7:e1002135.
26. Serrano M: SIRT1 Transgenic and Cancer Models. Orlando, FL: Proceedings of
the 102nd Annual Meeting of the AACR; 2011. Presentation SY11-03.
27. Saunders LR, Verdin E: Sirtuins: critical regulators at the crossroads
between cancer and aging. Oncogene 2007, 26:5489–5504.
28. Zhao G, Cui J, Zhang JG, Qin Q, Chen Q, Yin T, Deng SC, Liu Y, Liu L, Wang
B, Tian K, Wang GB, Wang CY: SIRT1 RNAi knockdown induces apoptosis
and senescence, inhibits invasion and enhances chemosensitivity in
pancreatic cancer cells. Gene Ther 2011, 18:920–928.
29. Sobin LH, Gospodarowicz MK, Wittekind C: UICC: TNM classification of
malignant tumors. 7th edition. Oxford: Wiley-Blackwell; 2009.
30. Bosman FT, Carneiro F, Hruban RH, Theise ND (Eds): WHO Classification of
Tumours of the Digestive System (IARC WHO Classification of Tumours), The
International Agency for Research on Cancer (Author). 4th edition. ; 2010.
31. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE,
Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP,
Sinclair DA, Alt FW, Greenberg ME: Stress-dependent regulation of FOXO
transcription factors by the SIRT1 deacetylase. Science 2004, 303:2011–2015.
32. Ehemann V, Hashemi B, Lange A, Otto HF: Flow cytometric DNA analysis
and chromosomal aberrations in malignant glioblastomas. Cancer Lett
1999, 138:101–106.
33. Wauters E, Sanchez-Arévalo Lobo VJ, Pinho AV, Mawson A, Herranz D, Wu J,
Cowley MJ, Colvin EK, Njicop EN, Sutherland RL, Liu T, Serrano M, Bouwens
L, Real FX Biankin AV, Rooman I: Sirtuin-1 Regulates Acinar-to-Ductal
Metaplasia and Supports Cancer Cell Viability in Pancreatic Cancer.
Cancer Res 2013, 66:2357–2367.
34. Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, Goehle S, Kollipara R,
Depinho RA, Gu Y, Simon JA, Bedalov A: Antitumor activity of a small-
molecule inhibitor of human silent information regulator 2 enzymes.
Cancer Res 2006, 66:4368–4377.
35. Simic P, Zainabadi K, Bell E, Sykes DB, Saez B, Lotinun S, Baron R, Scadden D,
Schipani E, Guarente L: SIRT1 regulates differentiation of mesenchymal
stem cells by deacetylating β-catenin. EMBO Mol Med 2013, 5:430–40.
36. Hong EH, Yun HS, Kim J, Um HD, Lee KH, Kang CM, Lee SJ, Chun JS, Hwang
SG: Nicotinamide phosphoribosyltransferase is essential for interleukin-
1beta-mediated dedifferentiation of articular chondrocytes via SIRT1 and
extracellular signal-regulated kinase (ERK) complex signaling. J Biol Chem
2011, 286:28619–31.
37. Chen HC, Jeng YM, Yuan RH, Hsu HC, Chen YL: SIRT1 promotes tumorigenesis
and resistance to chemotherapy in hepatocellular carcinoma and its
expression predicts poor prognosis. Ann Surg Oncol 2012, 19:2011–9.
38. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A, Nagy
TR: SIRT1 is significantly elevated in mouse and human prostate cancer.
Cancer Res 2007, 67:6612–8.
39. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL,
Yu JS: Analysis of gene expression and chemoresistance of CD133+
cancer stem cells in glioblastoma. Mol Cancer 2006, 5:67.
40. Nalls D, Tang SN, Rodova M, Srivastava RK, Shankar S: Targeting epigenetic
regulation of miR-34a for treatment of pancreatic cancer by inhibition of
pancreatic cancer stem cells. PLoS One 2011, 6e:24099.
41. Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, Mendell JT,
Maitra A: Restitution of tumor suppressor microRNAs using a systemic
nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther
2011, 10:1470–1480.
42. Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T, Holyoake TL, Chen W, Bhatia
R: Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML
Leukemia Stem Cells in Combination with Imatinib.
Cancer Cell 2012, 21:266–81.
Stenzinger et al. BMC Cancer 2013, 13:450 Page 12 of 12
http://www.biomedcentral.com/1471-2407/13/45043. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Klöppel G, Theis
B, Russell RC, Neoptolemos J, Williamson RC, et al: Abnormalities of the
p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer
1991, 64:1076–1082.
44. Ruggeri B, Zhang SY, Caamano J, DiRado M, Flynn SD, Klein-Szanto AJ:
Human pancreatic carcinomas and cell lines reveal frequent and
multiple alterations in the p53 and Rb-1 tumor-suppressor genes.
Oncogene 1992, 7:1503–1511.
45. Zhao G, Qin Q, Zhang J, Liu Y, Deng S, Liu L, Wang B, Tian K, Wang C:
Hypermethylation of HIC1 Promoter and Aberrant Expression of HIC1/SIRT1
Might Contribute to the Carcinogenesis of Pancreatic Cancer. Ann Surg
Oncol 2012. doi:DOI 10.1245/s10434-012-2364-9. May 3. [Epub ahead of print].
46. Huang S, Benavente S, Armstrong EA, Li C, Wheeler DL, Harari PM: p53
modulates acquired resistance to EGFR inhibitors and radiation. Cancer
Res 2011, 71:7071–7079.
47. Lowery MA, O'Reilly EM: Genomics and pharmacogenomics of pancreatic
adenocarcinoma. Pharmacogenomics J 2012, 12:1–9.
48. Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV, Dai Y: SIRT1
induces EMT by cooperating with EMT transcription factors and
enhances prostate cancer cell migration and metastasis.
Oncogene 2012, 31:4619–29.
49. Marks PA, Breslow R: Dimethyl sulfoxide to vorinostat: development of
this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol
2007, 25:84–90.
doi:10.1186/1471-2407-13-450
Cite this article as: Stenzinger et al.: High SIRT1 expression is a negative
prognosticator in pancreatic ductal adenocarcinoma. BMC Cancer
2013 13:450.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
